药物信息为Fluoxetine Hydrochloride (Northstar Rx LLC): ANIMAL PHARMACOLOGY/TOXICOLOGY
- BOXED WARNING
- DESCRIPTION
- CLINICAL TRIALS
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- ADVERSE REACTIONS
- DRUG ABUSE AND DEPENDENCE
- OVERDOSAGE
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- ANIMAL PHARMACOLOGY/TOXICOLOGY
- Medication Guide
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 10 mg (30 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 10 mg (100 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 10 mg (1000 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 20 mg (30 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 20 mg (100 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 20 mg (1000 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 40 mg (30 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 40 mg (100 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 40 mg (500 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 40 mg (1000 count)
- 外部链接相关的Fluoxetine Hydrochloride (Northstar Rx LLC)
- Phospholipids are increased in some tissues of mice, rats, and dogs given fluoxetine chronically. This effect is reversible after cessation of fluoxetine treatment. Phospholipid accumulation in animals has been observed with many cationic amphiphilic drugs, including fenfluramine, imipramine, and ranitidine. The significance of this effect in humans is unknown.
- Drug Information Provided by National Library of Medicine (NLM).
这个站点被设计主要作为提示系统供合格的医师和其他医疗专家使用。 通过使用这个站点您了解并且接受DiagnosisPro.com不会使用作为一个诊断决策系统，并且不能使用做一个临床诊断或替换或者否决一位被准许的医疗保健专家的评断或临床诊断 (充分的使用条款). 我们遵循健康网络基金会的 医学和健康网站的行为准则. 点击这里核实
© 2013 MedTech USA, Inc. (最后更新在05/23/13)
